Table 6 Studies describing hospital costs among patients with resistant and multi-drug resistant P. aeruginosa
From: Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review
Author | Bacteria | Comparison | Description of cost | Median cost in 2015 USD | Mean cost in 2015 USD | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Control | Median cost | Case | Control | Increase | Ratio | P-value | Mean cost | Case | Control | Increase | Ratio | P-value | |||
Chen et al. [91] | P. aeruginosa | CRPA | CSPA | Total hospital cost | Median (IQR) | 6122(3230–13,779) | 3191(1860–7313) | 2932(1370–6466) | 1.92 | < 0.001 |  |  |  |  |  |  |
P. aeruginosa | CRPA | CSPA | Total hospital cost | Median (IQR) | 5743(3147–11,957) | 4678(2602–9596) | 1065(545–2361) | 1.23 | 0.0150 |  |  |  |  |  |  | |
Lautenbach et al. [92] | P. aeruginosa | IRPA | ISPA | Total hospital cost | Median (IQR) | 111,871(39270–313,857) | 66,549(26338–180,391) | 45,322(12931–133,466) | 1.68 | < 0.001 |  |  |  |  |  |  |
Gasink et al. [93] | P. aeruginosa | Fluoroquinolones resistant P. aeruginosa | Fluoroquinolones susceptible P. aeruginosa | Total hospital charge | Median (IQR) | 85,729(30439–259,944) | 67,033(25805–171,704) | 18,696(4634–88,239) | 1.28 | 0.0080 |  |  |  |  |  |  |
Morales et al. [94] | P. aeruginosa | MDR | Non-resistant | Total hospital cost | Median (IQR) | 9810(7033–15,036) | 4132(2987–5058) | 5678(4046–9978) | 2.37 | < 0.001 | Mean (95% CI) | 22,503(17445–27,560) | 17,445(5765–8780) | 15,231(11680–18,780) | 3.09 | < 0.001 |
P. aeruginosa | Resistant | Non-resistant | Total hospital cost | Median (IQR) | 8961(7119–11,865) | 4132(2987–5058) | 4829(4132–6808) | 2.17 | < 0.001 | Mean (95% CI) | 18,207(13058–23,358) | 13,058(5765–8780) | 10,935(7293–14,578) | 2.50 | < 0.000 | |
Xu et al. [51] | P. aeruginosa | MDR | Non-MDR | Total hospital cost |  |  |  |  |  |  | Mean (SD) | 13,820(9536) | 9536(5450) | 9973(4087) | 3.59 | < 0.001 |
P. aeruginosa | MDR | Non-MDR | Antibiotic cost |  |  |  |  |  |  | Mean (SD) | 884(321) | 321(322) | 559(−1) | 2.72 | < 0.001 | |
Lautenbach et al. [95] | P. aeruginosa | IRPA | ISPA | Hospital cost after culture |  |  |  |  |  | Mean (95% CI) | 295,529(241780–349,278) | 241,780(177913–212,678) | 100,234(63867–136,600) | 1.51 | < 0.001 | |
Gasink et al. [96] | P. aeruginosa | Aztreonam resistant P. aeruginosa | Aztreonam susceptible P. aeruginosa | Hospital charge after culture | Median | 94,483 | 65,131 | 29,352 | 1.45 | 0.0100 | Â | Â | Â | Â | Â | Â |
Eagye et al. [97] | P. aeruginosa | MRPA | MSPA | Total cost (direct and indirect) | Median (IQR) | 103,907(28591–188,951) | 33,631(13529–103,906) | 70,276(15062–85,045) | 3.09 | < 0.001 |  |  |  |  |  |  |
P. aeruginosa | MRPA | Without infection | Total cost (direct and indirect) | Median (IQR) | 103,907(28591–188,951) | 26,563(18012–41,908) | 77,344(10579–147,042) | 3.91 | < 0.001 |  |  |  |  |  |  | |